# A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

> **NCT02266927** · PHASE1 · COMPLETED · sponsor: **Optinose US Inc.** · enrollment: 28 (actual)

## Conditions studied

- Mild to Moderate Asthma

## Interventions

- **DRUG:** Flovent HFA
- **DRUG:** OPTINOSE™ FLUTICASONE

## Key facts

- **NCT ID:** NCT02266927
- **Lead sponsor:** Optinose US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02266927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02266927, "A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02266927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*